Results 241 to 250 of about 396,678 (362)
Abstract Background The optimal design for care delivery in Parkinson's disease (PD) that addresses changing needs of the lived experience is unclear. There is a critical need for care models to be implemented and transferable across diverse healthcare systems with agility.
Deepa Dash +34 more
wiley +1 more source
How do psychedelics impact people with a history of non-affective psychosis? A qualitative study. [PDF]
Dourron HM +8 more
europepmc +1 more source
Abstract Objective Investigate the efficacy of immediate‐release (IR) amantadine in reducing the risk of peak‐dose dyskinesia in early Parkinson's disease (PD) as add‐on to levodopa. Background While the use of amantadine to manage dyskinesia in PD is well supported by controlled clinical trials, data on its efficacy in patients without motor ...
Olivier Rascol +106 more
wiley +1 more source
Amphetamine Versus Non Amphetamine-Related First Episode Psychosis in Saudi Arabian Patients
Ehab S. EL Desoky +3 more
openalex +2 more sources
Bipolar Disorder as a Long‐Term Risk Factor for Parkinson's Disease: A Nationwide Case–Control Study
Abstract Background Previous studies suggest an association between bipolar disorder (BD) and an increased risk of Parkinson's disease (PD), but the long‐term temporal relationship remains unclear. Particularly, it is unclear whether the risk of PD is influenced by the duration since BD diagnosis.
Elina Jaakkola +5 more
wiley +1 more source
Decoding brain structure-function dynamics in health and in psychosis via an autoencoder. [PDF]
Cai Q +7 more
europepmc +1 more source
Emotional intelligence mediated the association between interpersonal mindfulness and bullying victimization/perpetration (BV/BP). Higher interpersonal mindfulness was significantly associated with higher emotional intelligence. Higher emotional intelligence was significantly associated with lower BV/BP.
Marguerita Aoun +7 more
wiley +1 more source
ABSTRACT Background Clozapine initiation often triggers inflammatory responses that can alter metabolism via Cytochrome P450 1A2 (CYP1A2) suppression. Although C‐reactive protein (CRP) is the recommended marker, it may be unavailable in community settings.
Nicoline Bihelek +3 more
wiley +1 more source

